Physician profile
John Schinner
NPI 1619284171
$3,547.64
in general payments reported to CMS, 2019-2025
46 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $494 · 2021: $412 · 2022: $402 · 2023: $532 · 2024: $805 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.36 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $326.56 | 2019-2025 | |
| Lilly USA, LLC | $270.02 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.69 | 2020-2025 | Jardiance, Jascayd |
| Amarin Pharma, INC. | $125.68 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $117.36 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Novo Nordisk INC | $116.38 | 2020-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $116.05 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $105.83 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $83.55 | 2020-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $81.23 | 2021-2024 | Gardasil 9, Proquad, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.27 | 2020-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $69.60 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $67.00 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $58.88 | 2021-2024 | Farxiga, Airsupra |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.